Incyte (INCY) Cash & Current Investments (2010 - 2026)
Incyte (INCY) posted Cash & Current Investments of $4.0 billion for Q1 2026, up 12.15% on a QoQ basis from $3.6 billion in Q4 2025, and up 66.72% year-over-year from $2.4 billion in Q1 2025.
Incyte (INCY) Cash & Current Investments (2010 - 2026) Analysis & Trends
Incyte's Cash & Current Investments history runs 17 years deep, the most recent figure standing at $4.0 billion for Q1 2026.
- Quarterly Cash & Current Investments rose 66.72% year-over-year to $4.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 billion (up 66.72% YoY) and the FY2025 annual result came in at $3.6 billion, up 65.92% from the prior year.
- Cash & Current Investments was $4.0 billion for Q1 2026 at Incyte, up from $3.6 billion in the prior quarter.
- Across five years, Cash & Current Investments topped out at $4.0 billion in Q1 2026 and bottomed at $1.1 billion in Q2 2024.
- A 5-year average of $2.9 billion and a median of $3.0 billion in 2022 frame the typical range for Cash & Current Investments.
- Annual changes were most pronounced in 2024 — Cash & Current Investments slumped 69.12% — and 2025, when it surged 129.08%.
- Incyte's Cash & Current Investments stood at $3.2 billion in 2022, then increased by 12.88% to $3.7 billion in 2023, then slumped by 40.97% to $2.2 billion in 2024, then jumped by 65.92% to $3.6 billion in 2025, then climbed by 12.15% to $4.0 billion in 2026.
- Business Quant data shows INCY's Cash & Current Investments at $4.0 billion in Q1 2026, $3.6 billion in Q4 2025, and $2.9 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Incyte | 23.64 Bn | 19.62 Bn | 1.17 Bn | 4.02 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.02 Bn |
| Dec 31, 2025 | 3.58 Bn |
| Sep 30, 2025 | 2.93 Bn |
| Jun 30, 2025 | 2.42 Bn |
| Mar 31, 2025 | 2.41 Bn |
| Dec 31, 2024 | 2.16 Bn |
| Sep 30, 2024 | 1.77 Bn |
| Jun 30, 2024 | 1.06 Bn |
| Mar 31, 2024 | 3.85 Bn |
| Dec 31, 2023 | 3.66 Bn |
| Sep 30, 2023 | 3.52 Bn |
| Jun 30, 2023 | 3.42 Bn |
| Mar 31, 2023 | 3.11 Bn |
| Dec 31, 2022 | 3.24 Bn |
| Sep 30, 2022 | 2.98 Bn |
| Jun 30, 2022 | 2.72 Bn |
| Mar 31, 2022 | 2.54 Bn |
| Dec 31, 2021 | 2.35 Bn |
| Sep 30, 2021 | 2.28 Bn |
| Jun 30, 2021 | 2.08 Bn |